MacroGenics, Inc.
MGNX
Rank in Stocks
#18059
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers,... MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The companyโs product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Share Price
$2.20
Last synced: 2026-11-13
Market Cap
$140.24M
Change (1 day)
-3.93%
Change (1 year)
60.58%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade MacroGenics, Inc. (MGNX)
Category
Healthcare
EPS for MacroGenics, Inc. (MGNX)
EPS as of September 2026 TTM: $-0.81
According to MacroGenics, Inc.'s latest financial reports, its current EPS (TTM) is $-0.81. At the end of 2025 the company had an EPS of $-1.18, a decrease compared to its 2024 EPS of $-1.07.
EPS history for MacroGenics, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.81 | -31.36% |
| 2025 | $-1.18 | 10.28% |
| 2024 | $-1.07 | 613.33% |
| 2023 | $-0.15 | -92.31% |
| 2022 | $-1.95 | -42.14% |
| 2021 | $-3.37 | 36.44% |
| 2020 | $-2.47 | -21.84% |
| 2019 | $-3.16 | -24.58% |
| 2018 | $-4.19 | 675.93% |
| 2017 | $-0.54 | -68.05% |
| 2016 | $-1.69 | 168.25% |
| 2015 | $-0.63 | -55.00% |
| 2014 | $-1.40 | 13,625.49% |
| 2013 | $-0.01 | -102.22% |
| 2012 | $0.46 | 24.32% |
| 2011 | $0.37 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | 9.88% |
US
|
|
| $15.66 | -2,033.33% |
US
|
|
| $-7.07 | 772.84% |
US
|
|
| $-5.29 | 553.09% |
AU
|
|
| $12.73 | -1,671.88% |
BE
|
Questions about MacroGenics, Inc.'s earnings per share (EPS)
What is MacroGenics, Inc.'s earnings per share (EPS)?
MacroGenics, Inc.'s earnings per share (EPS) over the last twelve months is $-0.81, as of Sep 2026.
What was MacroGenics, Inc.'s earnings per share (EPS) in 2025?
In 2025, MacroGenics, Inc.'s earnings per share (EPS) was $-1.18, compared with $-1.07 in 2024.
How has MacroGenics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, MacroGenics, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.15) and lowest in 2021 ($-3.37).
How does MacroGenics, Inc.'s earnings per share (EPS) compare with similar companies?
MacroGenics, Inc.'s earnings per share (EPS) ($-0.81) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.